StemBoost Reprogramming Cocktail
To Order Contact us: bjorn@lembcke.dk
StemBoost? Neural Stem Cell Reprogramming Cocktail (100X) |
|||
S238-1 | Biovision | EUR 222 |
StemBoost? Neural Stem Cell Reprogramming Cocktail (100X) |
|||
S238-5 | Biovision | EUR 705.6 |
StemBoost? Cardiac Cell Reprogramming Cocktail SCPF (100X) |
|||
S243-1 | Biovision | EUR 222 |
StemBoost? Cardiac Cell Reprogramming Cocktail SCPF (100X) |
|||
S243-5 | Biovision | EUR 705.6 |
StemBoost? Neuronal Fate Reprogramming Cocktail FICB (10X) |
|||
S244-1 | Biovision | EUR 222 |
StemBoost? Neuronal Fate Reprogramming Cocktail FICB (10X) |
|||
S244-5 | Biovision | EUR 705.6 |
StemBoost? Reprogramming Cocktail, VCRFBI, Sterile-Filtered (100X) |
|||
S246-1 | Biovision | EUR 301.2 |
StemBoost? Reprogramming Cocktail, VCRFBI, Sterile-Filtered (100X) |
|||
S246-set | Biovision | EUR 1005.6 |
StemBoost? Reprogramming Cocktail, 3i (1000X), Sterile-Filtered |
|||
S247-1 | Biovision | EUR 235.2 |
StemBoost? Reprogramming Cocktail, 3i (1000X), Sterile-Filtered |
|||
S247-5 | Biovision | EUR 718.8 |
StemBoost? Reprogramming Cocktail, 3i (1000X), Sterile-Filtered |
|||
S247-set | Biovision | EUR 744 |
StemBoost? Reprogramming Cocktail Set I (1000X), Sterile-Filtered |
|||
K869-1ML | Biovision | EUR 314.4 |
StemBoost? Reprogramming Cocktail Set I (1000X), Sterile-Filtered |
|||
K869-5ML | Biovision | EUR 966 |
StemBoost? Reprogramming Cocktail Set I (1000X), Sterile-Filtered |
|||
K869-set | Biovision | EUR 1018.8 |
StemBoost? Reprogramming Cocktail Set II (1000X), Sterile-Filtered |
|||
K870-1ML | Biovision | EUR 314.4 |
StemBoost? Reprogramming Cocktail Set II (1000X), Sterile-Filtered |
|||
K870-5ML | Biovision | EUR 966 |
StemBoost? Reprogramming Cocktail Set II (1000X), Sterile-Filtered |
|||
K870-set | Biovision | EUR 1005.6 |
StemBoost? 2i-Reprogramming Cocktail Set (1000X), Sterile-Filtered |
|||
K889-1ML | Biovision | EUR 222 |
StemBoost? 2i-Reprogramming Cocktail Set (1000X), Sterile-Filtered |
|||
K889-5ML | Biovision | EUR 705.6 |
StemBoost? 2i-Reprogramming Cocktail Set (1000X), Sterile-Filtered |
|||
K889-set | Biovision | EUR 744 |
StemBoost? Fate Maintenance Medium (FMM) Cocktail |
|||
S232-1 | Biovision | EUR 301.2 |
StemBoost? Fate Maintenance Medium (FMM) Cocktail |
|||
S232-5 | Biovision | EUR 952.8 |
StemBoost? Fate Maintenance Medium (FMM) Cocktail |
|||
S232-set | Biovision | EUR 992.4 |
StemBoost? YPAC Cocktail Set (1000X), Sterile-Filtered |
|||
K871-1ML | Biovision | EUR 352.8 |
StemBoost? YPAC Cocktail Set (1000X), Sterile-Filtered |
|||
K871-5ML | Biovision | EUR 1083.6 |
StemBoost? YPAC Cocktail Set (1000X), Sterile-Filtered |
|||
K871-set | Biovision | EUR 1149.6 |
StemBoost? Nociceptor Induction Cocktail Set (1000X), Sterile-Filtered |
|||
K878-1000 | Biovision | EUR 352.8 |
StemBoost? Nociceptor Induction Cocktail Set (1000X), Sterile-Filtered |
|||
K878-500 | Biovision | EUR 222 |
StemBoost™ iN (induced Neuron) Conversion Cocktail, ZAPK |
|||
S250-1 | Biovision | 1 ml | EUR 272.4 |
StemBoost™ iN (induced Neuron) Conversion Cocktail, ZAPK |
|||
S250-5 | Biovision | 5 ml | EUR 903.6 |
StemBoost™ iN (induced Neuron) Conversion Cocktail, ZAPK |
|||
S250-set | Biovision | 5 x 1 ml | EUR 940.8 |
StemBoost? SMAD Signaling Inhibitor Cocktail Set (1000X), Sterile-Filtered |
|||
K877-1-ML | Biovision | EUR 183.6 |
StemBoost? SMAD Signaling Inhibitor Cocktail Set (1000X), Sterile-Filtered |
|||
K877-5-ML | Biovision | EUR 548.4 |
StemBoost? SMAD Signaling Inhibitor Cocktail Set (1000X), Sterile-Filtered |
|||
K877-set | Biovision | EUR 614.4 |
StemBoost? Neuronal Cell Induction Cocktail Set (100X), Sterile-Filtered |
|||
K891-1 | Biovision | EUR 314.4 |
StemBoost? Neuronal Cell Induction Cocktail Set (100X), Sterile-Filtered |
|||
K891-set | Biovision | EUR 966 |
Episomal iPSC Reprogramming System |
|||
SC900A-1 | SBI | 5 reactions | EUR 1161.6 |
StemBoost? Growth Factor Set V |
|||
K881-4 | Biovision | EUR 836.4 |
StemBoost? Growth Factor Set VI |
|||
K882-2 | Biovision | EUR 652.8 |
StemBoost? Growth Factor Set VII |
|||
K883-4 | Biovision | EUR 836.4 |
StemBoost? Growth Factor Set VIII |
|||
K884-2 | Biovision | EUR 652.8 |
StemBoost? Growth Factor Set IX |
|||
K885-3 | Biovision | EUR 652.8 |
StemBoost? Growth Factor Set X |
|||
K886-3 | Biovision | EUR 652.8 |
Growth Factor Set IV, StemBoost? |
|||
K426-5 | Biovision | EUR 1024.8 |
Growth Factor Set I, StemBoost? |
|||
K423-3 | Biovision | EUR 652.8 |
Growth Factor Set II, StemBoost? |
|||
K424-3 | Biovision | EUR 652.8 |
Growth Factor Set III, StemBoost? |
|||
K425-3 | Biovision | EUR 652.8 |
Mouse iPSC Chemical Reprogramming Cocktails Kit |
|||
K1022-100 | ApexBio | Chemical Reprogramming Cocktail+Dual Inhibition (2i) Medium Additive for 100 mL medium | EUR 444 |
Mouse iPSC Chemical Reprogramming Cocktails Kit |
|||
K1022-500 | ApexBio | Chemical Reprogramming Cocktail+Dual Inhibition (2i) Medium Additive for 500 mL medium | EUR 613.2 |
Lineage Cocktail FITC |
|||
6K01-T050 | ExBio | 50 tests | EUR 244.8 |
Cytokeratin antibody cocktail |
|||
10R-6769 | Fitzgerald | 1 ml | EUR 672 |
Description: Mouse monoclonal Cytokeratin antibody cocktail |
CD117(Cocktail) Antibody |
|||
BNC041018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF405S conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC041018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF405S conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCAP1018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCAP1018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCB1018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), Biotin conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCB1018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), Biotin conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCP1018-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against CD117(Cocktail), PerCP conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCR1018-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against CD117(Cocktail), RPE conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC941018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF594 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC941018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF594 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCA1018-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against CD117(Cocktail), APC conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC811018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF680R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC811018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF680R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNUB1018-100 | Biotium | 100uL | EUR 250.8 |
Description: Primary antibody against CD117(Cocktail), Concentration: 0.2mg/mL |
CD117(Cocktail) Antibody |
|||
BNUB1018-500 | Biotium | 500uL | EUR 549.6 |
Description: Primary antibody against CD117(Cocktail), Concentration: 0.2mg/mL |
CD117(Cocktail) Antibody |
|||
BNCH1018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNCH1018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC881018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF488A conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC881018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF488A conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC681018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF568 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC681018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF568 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC471018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF647 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC471018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF647 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC401018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF640R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC401018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF640R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC431018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF543 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC431018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF543 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC551018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF555 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC551018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF555 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC611018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF660R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC611018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF660R conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC801018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF680 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC801018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF680 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC051018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF405M conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC051018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF405M conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC701018-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against CD117(Cocktail), CF770 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNC701018-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against CD117(Cocktail), CF770 conjugate, Concentration: 0.1mg/mL |
CD117(Cocktail) Antibody |
|||
BNUM1018-50 | Biotium | 50uL | EUR 474 |
Description: Primary antibody against CD117(Cocktail), 1mg/mL |
Protease Inhibitor Cocktail |
|||
G135 | ABM | 1.0 ml | EUR 190.8 |
Protease Inhibitor Cocktail |
|||
K271-500 | Biovision | EUR 280.8 |
Protease Inhibitor Cocktail |
|||
R-1101-1 | EpiGentek | 1 ml | EUR 79.2 |
Protease Inhibitor Cocktail |
|||
R-1101 | EpiGentek |
|
|
CD1a Antibody Cocktail |
|||
V2027-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody Cocktail |
|||
V2027-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody Cocktail |
|||
V2027IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD1a Antibody Cocktail |
|||
V2027SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). |
CD6 Antibody Cocktail |
|||
V2041-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
CD6 Antibody Cocktail |
|||
V2041-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
CD6 Antibody Cocktail |
|||
V2041IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
CD6 Antibody Cocktail |
|||
V2041SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD6 is a type I transmembrane glycoprotein that contains a 24-amino acid signal sequence, three extracellular “scavenger receptor cysteine-rich” (SRCR) domains, a membrane-spanning domain and a 44-amino acid cytoplasmic domain. The CD6 glycoprotein is tyrosine phosphorylated during TCR-mediated T cell activation. CD6 shows significant homology to CD5. CD6 is present on mature thymocytes, peripheral T cells and a subset of B cells. antibody to CD6 can be used to deplete T cells from bone marrow transplants to prevent graft versus host disease. |
CD68 Antibody Cocktail |
|||
V2075-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
CD68 Antibody Cocktail |
|||
V2075-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
CD68 Antibody Cocktail |
|||
V2075IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
CD68 Antibody Cocktail |
|||
V2075SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: This antibody cocktail recognizes a glycoprotein of 110kDa, which is identified as CD68. antibody to CD68 is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, in lamina propria of the gut, in lung alveoli, and in bone marrow. CD68 antibody reacts with myeloid precursors and peripheral blood granulocytes. It also reacts with plasmacytoid T cells, which are supposed to be of monocyte/macrophage origin. CD68 shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with rare cases of true histiocytic neoplasia. Lymphomas are negative or show few granules. |
CD79a Antibody Cocktail |
|||
V2080-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. |
CD79a Antibody Cocktail |
|||
V2080-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. |
CD79a Antibody Cocktail |
|||
V2080IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. |
CD79a Antibody Cocktail |
|||
V2080SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. |